Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 preoperative window study of SAR439859 versus letrozole in ER-positive, HER2-negative primary breast cancer
2019-002015-26Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amcenestrant in breast cancer (3 arms), sponsored by Sanofi. Primary endpoint: Change in Ki67. Started Oct 2019; status: completed.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-002015-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002015-26.